
    
      This is a single-patient study to assess the safety and efficacy of setmelanotide in a unique
      patient with partal LD and severe metabolic abnormalities, most notably refractory
      hypertriglyceridemia leading to recurrent pancreatitis despite ongoing plasmapheresis
      treatment.
    
  